Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of QL1207H versus Eylea in neovascular age-related macular degeneration
CTR20261002Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in exudative macular degeneration (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Change from baseline in BCVA letter score at Week 12. Started Mar 2026; status: active.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20261002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261002.